AbbVie Inc. avoided calling the Phase II TRINITY data it unveiled March 22 for rovalpituzumab tesirine (Rova-T) in small cell lung cancer a failure, but market analysts took no such precautions, with one saying the unconvincing data might "unravel AbbVie's oncology strategy."
The dire prognosis came from Leerink Partners analyst Geoffrey Porges, but he wasn't alone in seeing the unimpressive data for...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)